Alcohol Dehydrogenase 4-Mediated Retinol Metabolism Inhibits Hepatocellular Carcinoma Progression Through Inhibiting the Wnt/β-Catenin Pathway

Abstract

Hepatocellular carcinoma (HCC) ranks third in global cancer-related mortality, with limited therapies for advanced stages. Retinol, the alcohol form of vitamin A, has long been associated with liver diseases. Plasma retinol levels have been inversely correlated with the risk and poor prognosis of HCC. In this study, transcriptome data analysis identified retinol metabolism as the seventh KEGG-dysregulated pathway in cirrhosis tissue, ascending to the top position in HCC tissue compared to normal tissue. Specifically, a consistent downregulation of ADH4 (alcohol dehydrogenase 4), the retinol dehydrogenase among human ADHs, was observed, which correlated with poor prognosis in HCC patients. In vivo experiments demonstrated that silencing ADH4 enhances liver fibrosis and the progression of HCC. Mechanistically, ADH4 elevated intracellular levels of RA (retinoic acid), a biologically active derivative of retinol. RA-activated retinoid receptors RARs/RXRs, leading to inhibition of the downstream Wnt/β-catenin pathway and thereby hindering HCC progression. In contrast, the knockdown of ADH4 in hepatocytes triggers apoptosis. Notably, additional results demonstrated that the combined treatment of RA and cisplatin achieved synergistic antitumor effects in a mouse HCC model. In summary, our research elucidates that ADH4-mediated RA production suppresses HCC growth, providing a theoretical foundation for HCC treatment.

Keywords

alcohol dehydrogenase 4 / hepatocellular carcinoma (HCC) / retinol metabolism / Wnt/β-catenin pathway

References

[1] M. Kudo, O. Matsui, N. Izumi, et al., “JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan,” Liver Cancer 3, no. 3–4 (2014): 458–468.

[2] W. Yeo, T. S. Mok, B. Zee, et al., “A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular Carcinoma,” JNCI: Journal of the National Cancer Institute 97, no. 20 (2005): 1532–1538.

[3] J. Y. Park, S. H. Ahn, Y. J. Yoon, et al., “Repetitive Short-Course Hepatic Arterial Infusion Chemotherapy With High-Dose 5-Fluorouracil and Cisplatin in Patients With Advanced Hepatocellular Carcinoma,” Cancer 110, no. 12007): 129–137.

[4] M. Kudo, K. Ueshima, O. Yokosuka, et al., “Sorafenib Plus Low-Dose Cisplatin and Fluorouracil Hepatic Arterial Infusion Chemotherapy Versus Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma (SILIUS): A Randomised, Open Label, Phase 3 Trial,” Lancet Gastroenterology & Hepatology 3, no. 6 (2018): 424–432.

[5] B. Faubert, A. Solmonson, and R. J. DeBerardinis, “Metabolic Reprogramming and Cancer Progression,” Science 368, no. 6487 (2020): eaaw5473.

[6] D. DeWaal, V. Nogueira, A. R. Terry, et al., “Hexokinase-2 Depletion Inhibits Glycolysis and Induces Oxidative Phosphorylation in Hepatocellular Carcinoma and Sensitizes to Metformin,” Nature Communications 9, no. 1 (2018): 446.

[7] B. Li, Y. Cao, G. Meng, et al., “Targeting Glutaminase 1 Attenuates Stemness Properties in Hepatocellular Carcinoma by Increasing Reactive Oxygen Species and Suppressing Wnt/Beta-Catenin Pathway,” EBioMedicine 39 (2019): 239–254.

[8] A. Du, Z. Wang, T. Huang, et al., “Fatty Acids in Cancer: Metabolic Functions and Potential Treatment,” MedComm – Oncology 2, no. 1 (2023): e25.

[9] M. Mark, N. B. Ghyselinck, and P. Chambon, “Function of Retinoid Nuclear Receptors: Lessons From Genetic and Pharmacological Dissections of the Retinoic Acid Signaling Pathway During Mouse Embryogenesis,” Annual Review of Pharmacology and Toxicology 46 (2006): 451–480.

[10] N. Martinet, F. Alla, G. Farré, et al., “Retinoic Acid Receptor and Retinoid X Receptor Alterations in Lung Cancer Precursor Lesions,” Cancer Research 60, no. 11 (2000): 2869–2875.

[11] Y. Sun, L. Liu, Y. Fu, et al., “Metabolic Reprogramming Involves in Transition of Activated/Resting CD4(+) Memory T Cells and Prognosis of Gastric Cancer,” Frontiers in Immunology 14 (2023): 1275461.

[12] A. K. Meligova, D. Siakouli, S. Stasinopoulou, et al., “ERβ1 Sensitizes and ERβ2 Desensitizes ERα-Positive Breast Cancer Cells to the Inhibitory Effects of Tamoxifen, Fulvestrant and Their Combination With All-Trans Retinoic Acid,” International Journal of Molecular Sciences 24, no. 4 (2023): 3747.

[13] Y. Song, P. Peng, C. Qiao, J. Li, Q. Long, and H. Lu, “Potential Effects of the FLT3-ITD Mutation on Chemotherapy Response and Prognosis of Acute Promyelocytic Leukemia,” Cancer Management and Research 13 (2021): 2371–2378.

[14] X. H. Tang and L. J. Gudas, “Retinoids, Retinoic Acid Receptors, and Cancer,” Annual Review of Pathology: Mechanisms of Disease 6 (2011): 345–364.

[15] J. Srivastava, C. L. Robertson, D. Rajasekaran, et al., “AEG-1 Regulates Retinoid X Receptor and Inhibits Retinoid Signaling,” Cancer Research 74, no. 16 (2014): 4364–4377.

[16] M. Li, Y. Sun, X. Guan, X. Shu, and C. Li, “Advanced Progress on the Relationship Between RA and Its Receptors and Malignant Tumors,” Critical Reviews in Oncology/Hematology 91, no. 3 (2014): 271–282.

[17] G. F. Zhang, L. Qiu, S. L. Yang, J. C. Wu, and T. J. Liu, “Wnt/Beta-Catenin Signaling as an Emerging Potential Key Pharmacological Target in Cholangiocarcinoma,” Bioscience Reports 40, no. 3 (2020): BSR20193353.

[18] E. F. Farias, C. Marzan, and R. Mira-y-Lopez, “Cellular Retinol-Binding Protein-I Inhibits PI3K/Akt Signaling Through a Retinoic Acid Receptor-Dependent Mechanism That Regulates p85-p110 Heterodimerization,” Oncogene 24, no. 9 (2005): 1598–1606.

[19] C. C. Applegate and M. A. Lane, “Role of Retinoids in the Prevention and Treatment of Colorectal Cancer,” World Journal of Gastrointestinal Oncology 7, no. 10 (2015): 184–203.

[20] X. Liu, W. Shan, T. Li, et al., “Cellular Retinol Binding Protein-1 Inhibits Cancer Stemness via Upregulating WIF1 to Suppress Wnt/β-Catenin Pathway in Hepatocellular Carcinoma,” BMC Cancer 21, no. 1 (2021): 1224.

[21] M. Suzui, M. Shimizu, M. Masuda, J. T. E. Lim, N. Yoshimi, and I. B. Weinstein, “Acyclic Retinoid Activates Retinoic Acid Receptor β and Induces Transcriptional Activation of p21^CIP1 in HepG2 Human Hepatoma Cells,” Molecular Cancer Therapeutics 3, no. 3 (2004): 309–316.

[22] R. Li, T. N. Faria, M. Boehm, E. G. Nabel, and L. J. Gudas, “Retinoic Acid Causes Cell Growth Arrest and an Increase in p27 in F9 Wild Type But Not in F9 Retinoic Acid Receptor β2 Knockout Cells,” Experimental Cell Research 294, no. 1 (2004): 290–300.

[23] D. Jeon, M. Son, and J. Shim, “Dynamics of Serum Retinol and Alpha-Tocopherol Levels According to Non-Alcoholic Fatty Liver Disease Status,” Nutrients 13, no. 5 (2021): 1720.

[24] M. Hada, A. M. Mondul, S. J. Weinstein, and D. Albanes, “Serum Retinol and Risk of Overall and Site-Specific Cancer in the ATBC Study,” American Journal of Epidemiology 189, no. 6 (2020): 532–542.

[25] L. Deltour, M. H. Foglio, and G. Duester, “Impaired Retinol Utilization in Adh4 Alcohol Dehydrogenase Mutant Mice,” Developmental Genetics 25, no. 1 (1999): 1520–6408.

[26] X. Liu, T. Li, D. Kong, H. You, F. Kong, and R. Tang, “Prognostic Implications of Alcohol Dehydrogenases in Hepatocellular Carcinoma,” BMC Cancer 20, no. 1 (2020): 1204.

[27] S. H. Karunakara, L. D. Puttahanumantharayappa, N. G. Sannappa Gowda, V. D. Shiragannavar, and P. K. Santhekadur, “Novel Insights Into MEG3/miR664a-3p/ADH4 Axis and Its Possible Role in Hepatocellular Carcinoma From an In Silico Perspective,” Genes 13, no. 12 (2022): 2254.

[28] D. Li, X. Lin, J. Li, et al., “Eleven Metabolism‑Related Genes Composed of Stard5 Predict Prognosis and Contribute to EMT Phenotype in HCC,” Cancer Cell International 23, no. 1 (2023): 277.

[29] J. L. Slack, “Biology and Treatment of Acute Progranulocytic Leukemia,” Current Opinion in Hematology 6, no. 4 (1999): 236–240.

[30] M. Rubin, E. Fenig, A. Rosenauer, et al., “9-Cis Retinoic Acid Inhibits Growth of Breast Cancer Cells and Down-Regulates Estrogen Receptor RNA and Protein,” Cancer Research 54, no. 24 (1994): 6549–6556.

[31] W. Y. Zhu, C. S. Jones, A. Kiss, K. Matsukuma, S. Amin, and L. M. De Luca, “Retinoic Acid Inhibition of Cell Cycle Progression in MCF-7 Human Breast Cancer Cells,” Experimental Cell Research 234, no. 2 (1997): 293–299.

[32] J. S. Kim, P. A. Steck, G. E. Gallick, et al., “Suppression by Retinoic Acid of Epidermal Growth Factor Receptor Autophosphorylation and Glycosylation in Cultured Human Head and Neck Squamous Carcinoma Cells,” Journal of the National Cancer Institute Monographs 13 (1992): 101–110.

[33] D. Mucida, Y. Park, G. Kim, et al., “Reciprocal TH17 and Regulatory T Cell Differentiation Mediated by Retinoic Acid,” Science 317, no. 5835 (2007): 256–260.

[34] P. Chambon, “A Decade of Molecular Biology of Retinoic Acid Receptors,” FASEB Journal 10, no. 9 (1996): 940–954.

[35] T. J. Cunningham and G. Duester, “Mechanisms of Retinoic Acid Signalling and Its Roles in Organ and Limb Development,” Nature Reviews Molecular Cell Biology 16, no. 2 (2015): 110–123.

[36] T. Malinauskas and E. Y. Jones, “Extracellular Modulators of Wnt Signalling,” Current Opinion in Structural Biology 29 (2014): 77–84.

[37] O. Tetsu and F. McCormick, “β-Catenin Regulates Expression of Cyclin D1 in Colon Carcinoma Cells,” Nature 398, no. 6726 (1999): 422–426.

[38] T. C. He, A. B. Sparks, C. Rago, et al., “Identification of c-MYC as a Target of the APC Pathway,” Science 281, no. 5382 (1998): 1509–1512.

[39] M. Ge, J. Luo, Y. Wu, G. Shen, and X. Kuang, “The Biological Essence of Synthetic Lethality: Bringing New Opportunities for Cancer Therapy,” MedComm – Oncology 3, no. 1 (2024): e70.

[40] E. Patrad, A. Niapour, F. Farassati, and M. Amani, “Combination Treatment of All-Trans Retinoic Acid (ATRA) and γ-Secretase Inhibitor (DAPT) Cause Growth Inhibition and Apoptosis Induction in the Human Gastric Cancer Cell Line,” Cytotechnology 70, no. 2 (2018): 865–877.

[41] H. J. Johansson, B. C. Sanchez, F. Mundt, et al., “Retinoic Acid Receptor Alpha Is Associated With Tamoxifen Resistance in Breast Cancer,” Nature Communications 4, no. 1 (2013): 2175.

[42] S. Huang, Y. Chen, Z. M. Liang, et al., “Targeting Pin1 by All-Trans Retinoic Acid (ATRA) Overcomes Tamoxifen Resistance in Breast Cancer via Multifactorial Mechanisms,” Frontiers in Cell and Developmental Biology 7 (2019): 322.

[43] F. Lo-Coco, G. Avvisati, M. Vignetti, et al., “Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia,” New England Journal of Medicine 369, no. 2 (2013): 111–121.

[44] X. Chen and D. F. Calvisi, “Hydrodynamic Transfection for Generation of Novel Mouse Models for Liver Cancer Research,” American Journal of Pathology 184, no. 4 (2014): 912–923.

[45] Q.-Y. Jiang, Y. Chen, R.-S. Li, et al., “A Novel Quantitative Analysis Method of In Situ Tumor Image of Liver in Nude Mice Based on Image J Software,” Letters in Biotechnology 29, no. 4 (2018): 541–546.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm – Oncology published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).